Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to -$974000.0.

  • Celldex Therapeutics' Change in Receivables rose 1433.6% to -$974000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$762000.0, marking a year-over-year decrease of 22700.0%. This contributed to the annual value of -$1.9 million for FY2024, which is 18452.43% down from last year.
  • Latest data reveals that Celldex Therapeutics reported Change in Receivables of -$974000.0 as of Q2 2025, which was up 1433.6% from $364000.0 recorded in Q1 2025.
  • Over the past 5 years, Celldex Therapeutics' Change in Receivables peaked at $2.4 million during Q4 2023, and registered a low of -$1.3 million during Q2 2021.
  • In the last 5 years, Celldex Therapeutics' Change in Receivables had a median value of $500.0 in 2021 and averaged -$92000.0.
  • Over the last 5 years, Celldex Therapeutics' Change in Receivables had its largest YoY gain of 140379.75% in 2023, and its largest YoY loss of 71917.81% in 2023.
  • Celldex Therapeutics' Change in Receivables (Quarter) stood at -$25000.0 in 2021, then skyrocketed by 732.0% to $158000.0 in 2022, then skyrocketed by 1403.8% to $2.4 million in 2023, then crashed by 106.4% to -$152000.0 in 2024, then crashed by 540.79% to -$974000.0 in 2025.
  • Its last three reported values are -$974000.0 in Q2 2025, $364000.0 for Q1 2025, and -$152000.0 during Q4 2024.